Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mesoblast Ltd (NASDAQ:MESO)

7.04
Delayed Data
As of 4:00pm ET
 -0.11 / -1.54%
Today’s Change
4.01
Today|||52-Week Range
12.50
+31.59%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$607.0M

Company Description

Mesoblast Ltd. engages in the research, development, and market of pharmaceutical products. Its medicines target the cardiovascular conditions, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Contact Information

Mesoblast Ltd.
Level 38
Melbourne Victoria (vic) 3000
P:(139) 639-6036
Investor Relations:
(212) 880-2060

Employees

Shareholders

Mutual fund holders2.35%
Other institutional0.53%
Individual stakeholders--

Top Executives

Silviu ItescuChief Executive Officer, MD & Executive Director
Paul HodgkinsonChief Financial Officer
Donna L. SkerrettChief Medical Officer
Michael SchusterHead-Pharma Partnering
Charlie HarrisonSecretary & Director